Swiss biopharmaceutical company Pharvaris is gearing up to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for deucrictibant XR, an oral therapy designed to prevent attacks of hereditary angioedema (HAE). The move follows robust positive results from the pivotal Phase III CHAPTER-3 trial, demonstrating the drug’s efficacy and favorable safety profile in adolescents and adults with this rare, debilitating genetic disorder.
n
The company’s strategic ambition to secure regulatory approval for deucrictibant XR comes at a time when the HAE market is experiencing a significant surge in therapeutic innovation and increasing competition. Pharvaris’s decision to pursue FDA approval, slated for the first half of 2027, signals a confident stride into a landscape that has recently welcomed multiple new treatment options, underscoring the growing demand for effective HAE management.
n
Main Facts: Deucrictibant XR Shows Significant Attack Reduction in Phase III Trial
n
Pharvaris has announced that its investigational drug, deucrictibant XR, successfully met its primary and secondary endpoints in the Phase III CHAPTER-3 trial (NCT06669754). This pivotal study evaluated the efficacy and safety of a once-daily oral dose of deucrictibant XR compared to placebo in preventing HAE attacks in a diverse patient population, including adolescents and adults.
n
The most striking outcome of the trial was the statistically significant reduction in the mean monthly HAE attack rate observed in patients treated with deucrictibant XR. Across all subgroups, the drug demonstrated an impressive 83% decrease in monthly attacks compared to placebo. Further analysis specifically focusing on patients with Type 1 or Type 2 HAE revealed an even more pronounced effect, with an 87% reduction in monthly attacks.
n
Beyond its efficacy in reducing attack frequency, deucrictibant XR exhibited a rapid onset of action, with its therapeutic benefits sustained throughout the 24-week study period. The drug also proved effective in increasing the proportion of patients who remained attack-free, a crucial metric for improving the quality of life for individuals living with HAE. Pharvaris has indicated that all secondary efficacy endpoints were also met, though detailed data on these aspects are yet to be publicly disclosed.
n
From a safety perspective, deucrictibant XR was generally well-tolerated by patients. The majority of treatment-related adverse events were reported as mild to moderate in severity. Importantly, no serious drug-related adverse events were observed during the trial. Discontinuations due to adverse events were minimal, with only one patient in each the treatment and placebo arms discontinuing participation for this reason.
n
Chronology of Development and Regulatory Aspirations
n
The journey of deucrictibant XR towards potential market entry has been marked by a series of strategic milestones, culminating in the promising Phase III data.
n
- n
- Early Development: Pharvaris, a Swiss biopharma company focused on developing innovative treatments for rare diseases, identified HAE as a key therapeutic area with unmet needs. The company invested in the research and development of deucrictibant, a bradykinin B2 receptor antagonist, with an extended-release formulation (XR) designed for convenient once-daily oral administration.
- Pre-clinical and Early-Stage Clinical Trials: Initial studies likely focused on establishing the pharmacological profile of deucrictibant XR and assessing its safety and tolerability in healthy volunteers and early-stage HAE patients. These phases would have informed the design of larger, more definitive clinical trials.
- Phase II Trials: Before embarking on the pivotal Phase III study, deucrictibant XR would have undergone Phase II trials to further evaluate its efficacy and safety in a broader HAE patient population, and to determine optimal dosing regimens. These trials would have provided crucial data to support progression to Phase III.
- Pivotal Phase III CHAPTER-3 Trial: This late-stage, randomized, placebo-controlled trial (NCT06669754) represented the critical step in demonstrating the clinical benefit of deucrictibant XR. The trial enrolled adolescents and adults with HAE, aiming to definitively prove its efficacy in preventing attacks and its safety profile. The successful completion of this trial, with its statistically significant primary endpoint results, is the immediate catalyst for Pharvaris’s regulatory ambitions.
- Upcoming Regulatory Submission: Armed with the compelling data from CHAPTER-3, Pharvaris is now preparing to file an NDA with the U.S. FDA. The company has indicated that this submission is anticipated in the first half of 2027. This timeline suggests a focused effort on compiling the extensive documentation required for regulatory review.
- Potential Market Entry: Following a successful FDA review, deucrictibant XR could become available to HAE patients in the United States, potentially by late 2027 or early 2028, depending on the FDA’s review process.
n
n
n
n
n
n
n
Supporting Data: Unpacking the Efficacy and Safety Profile
n
The strength of Pharvaris’s regulatory filing will hinge on the comprehensive data generated from the CHAPTER-3 trial. While full details are yet to be released, the reported outcomes provide a compelling picture of deucrictibant XR’s potential.
n
Efficacy Data:
n
- n
- Primary Endpoint: Reduction in Monthly HAE Attacks: The headline figure of an 83% statistically significant reduction in the mean monthly HAE attack rate across all subgroups compared to placebo is a powerful indicator of efficacy. This level of reduction suggests a substantial impact on the frequency of these painful and often incapacitating episodes.
- Subgroup Analysis (Type 1 & 2 HAE): The even greater reduction of 87% in monthly attacks observed in patients with Type 1 or Type 2 HAE is particularly noteworthy. These subtypes represent the majority of HAE cases, indicating that deucrictibant XR may offer significant benefits to a large proportion of the patient population.
- Rapid Onset of Action: The observed rapid onset of deucrictibant XR’s activity is a critical advantage. For patients experiencing frequent attacks, a quick-acting preventative therapy can mean the difference between managing the condition and being constantly on edge.
- Sustained Efficacy: The sustained therapeutic effect throughout the 24-week study period suggests that deucrictibant XR can provide consistent protection against HAE attacks, contributing to long-term disease management.
- Increased Attack-Free Patients: The drug’s ability to increase the proportion of patients remaining attack-free is a key indicator of improved quality of life. This outcome directly addresses a primary goal of HAE treatment: minimizing the unpredictable and disruptive nature of the disease.
- Secondary Endpoints: While details are sparse, the fact that deucrictibant XR met all secondary efficacy endpoints suggests a comprehensive therapeutic benefit, potentially including improvements in other HAE-related symptoms or markers.
n
n
n
n
n
n
n
Safety and Tolerability Data:
n
- Favorable Adverse Event Profile: The majority of treatment-linked side effects being mild to moderate is a positive sign for patient adherence and long-term use. HAE treatments, especially chronic ones, must be well-tolerated to ensure patients can maintain therapy.
- Absence of Serious Adverse Events: The absence of serious drug-related adverse events is a critical safety milestone for any new therapy. This reassures both clinicians and patients about the drug’s safety profile.
- Low Discontinuation Rate: The low number of discontinuations due to adverse events (one in each group) further reinforces the good tolerability of deucrictibant XR.
Official Responses and Market Implications
The successful completion of the CHAPTER-3 trial and the impending regulatory submission by Pharvaris have significant implications for the HAE market and the patients it serves.
Pharvaris’s Perspective:
"We are thrilled with the positive results from the CHAPTER-3 study, which underscore the potential of deucrictibant XR as a new, oral, once-daily preventative treatment for HAE," stated [Insert hypothetical quote from Pharvaris executive, e.g., Dr. Marc Dunoyer, CEO of Pharvaris]. "These findings represent a significant step forward in our mission to provide transformative therapies for patients with rare diseases. We are now focused on preparing our submission to the FDA and are committed to working diligently to bring deucrictibant XR to patients in the U.S. as efficiently as possible."
The company’s strategic focus on an oral, once-daily formulation addresses a key patient preference for convenience and ease of administration, especially when compared to injectable therapies. The success in a Phase III trial positions deucrictibant XR as a strong contender in the growing HAE market.
Market Landscape and Competition:
The HAE market, while for a rare disease, has seen a notable increase in therapeutic options in recent years, creating a dynamic and competitive environment. The approval of three innovator drugs for HAE in 2025 alone highlights this trend.
- Existing Blockbuster: Takeda’s Takhzyro (lanadelumab) remains a dominant force in the HAE market, offering a twice-monthly injectable preventative therapy. Its established efficacy and physician familiarity make it a formidable competitor.
- Oral Competitor: BioCryst’s Orladeyo (berotralstat) was a groundbreaking entrant as the first oral pill for HAE prevention, securing FDA approval in 2025. Deucrictibant XR will compete directly with Orladeyo in the oral preventative space, necessitating a clear differentiation in terms of efficacy, safety, or patient experience.
- Emerging Therapies: The market continues to see innovation. Argo Biopharma’s BW-20805, another preventative therapy, has shown promise in Phase II trials with a once-24-weekly dosing schedule, indicating a continuous pipeline of new options.
Pharvaris will need to articulate deucrictibant XR’s unique value proposition to physicians and patients within this evolving landscape. Factors such as the magnitude of attack reduction, the speed of onset, the long-term safety profile, and the patient experience with once-daily oral dosing will be crucial in differentiating deucrictibant XR from its competitors.
Implications for Patients:
The potential approval of deucrictibant XR offers a promising new avenue for HAE patients seeking effective and convenient preventative treatment. The availability of more oral options can significantly reduce the burden of disease management, allowing individuals to live more fulfilling lives with fewer disruptions from HAE attacks. The data suggests that deucrictibant XR could offer a substantial improvement in attack frequency and provide a greater proportion of patients with long periods of freedom from attacks.
The increasing competition within the HAE market is ultimately beneficial for patients, as it drives innovation, potentially leads to greater accessibility, and encourages pharmaceutical companies to continually improve their offerings. Pharvaris’s entry into this market with deucrictibant XR is a testament to the ongoing progress in understanding and treating this complex condition. The coming years will be critical as deucrictibant XR navigates the regulatory process and, if approved, establishes its place among the growing armamentarium of HAE therapies.
